At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MYNZ Mainz Biomed B.V.
Market Closed 02-27 16:00:00 EST
0.7600
+0.0232
+3.15%
盘后0.7699
+0.0099+1.30%
19:47 EST
High0.7692Low0.7170Vol182.95K
Open0.7200D1 Closing0.7368Amplitude7.08%
Mkt Cap6.89MTradable Cap6.85MTotal Shares9.06M
T/O135.69KT/O Rate2.03%Tradable Shares9.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session
Reuters  ·  02-24
Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session
Mainz Biomed NV Files Initial Beneficial Ownership Statement for Director Hans Hekland
Reuters  ·  02-20
Mainz Biomed NV Files Initial Beneficial Ownership Statement for Director Hans Hekland
Mainz Biomed Secures $6 Million in Private Placement
Reuters  ·  02-17
Mainz Biomed Secures $6 Million in Private Placement
Press Release: Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
Dow Jones  ·  02-17
Press Release: Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
Mainz Biomed completes ATM share sales, retains capacity
TIPRANKS  ·  02-11
Mainz Biomed completes ATM share sales, retains capacity
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler
Reuters  ·  01-27
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler
Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed
TIPRANKS  ·  01-17
Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed
Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner
Reuters  ·  01-17
Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner
Mainz Biomed Unveils Pancreatic Cancer mRNA Blood Test Study Results at AACR 2026
Reuters  ·  01-14
Mainz Biomed Unveils Pancreatic Cancer mRNA Blood Test Study Results at AACR 2026
Mainz Biomed Provides Review of 2025 Highlights
GlobeNewswire  ·  01-05
Mainz Biomed Provides Review of 2025 Highlights
Mainz Biomed Secures State Funding for Pancreatic Cancer Detection Project
Reuters  ·  01-05
Mainz Biomed Secures State Funding for Pancreatic Cancer Detection Project
Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test
Reuters  ·  2025-12-02
Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test
Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America
Reuters  ·  2025-11-18
Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America
Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA
Reuters  ·  2025-11-12
Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA
Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting
Reuters  ·  2025-11-10
Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting
Mainz Biomed NV to Attend Maxim Growth Summit in New York City
Reuters  ·  2025-10-15
Mainz Biomed NV to Attend Maxim Growth Summit in New York City
Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study
Reuters  ·  2025-10-08
Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study
Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement
Reuters  ·  2025-10-04
Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement
Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting
Reuters  ·  2025-09-30
Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting
Mainz Biomed Reports Financial Results for First Half of 2025
TIPRANKS  ·  2025-09-27
Mainz Biomed Reports Financial Results for First Half of 2025

Introduction

Company Name.
Mainz Biomed B.V.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Issue price:
--